Citations

Clear

219 citation(s) found for "Do, Ron".

Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study
Mutsaerts, Henk , Mirza, Saira Saeed , Petr, Jan , Thomas, David L. , Cash, David M. , Bocchetta, Martina , Metcalfe, Arron W.S. , Shirzadi, Zahra , Robertson, Andrew D. , Tartaglia, Maria Carmela , Mitchell, Sara, Freedman, Morris , Tang‐Wai, David F. , Keren, Ron , Laforce, Robert , Tagliavini, Fabrizio , Borroni, Barbara , Galimberti, Daniela , Rowe, James B. , Graff, Caroline , Frisoni, Giovanni B. , Finger, Elizabeth , Sorbi, Sandro , Mendonça, Alexandre de , Rohrer, Jonathan D. , MacIntosh, Bradley J. , (GENFI), GENetic Frontotemporal dementia Initiative, Andersson, Christin, Archetti, Silvana, Arighi, Andrea , Benussi, Luisa , Binetti, Giuliano, Cosseddu, Maura , Dick, Katrina M., Fallström, Marie, Fenoglio, Chiara , Fumagalli, Giorgio, Gazzina, Stefano , Ghidoni, Roberta , Grisoli, Marina , Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Mead, Simon , Meeter, Lieke , Minkelen, Rick van , Öijerstedt, Linn , Ourselin, Sébastien , Padovani, Alessandro , Panman, Jessica , Pievani, Michela, Polito, Cristina , Premi, Enrico, Prioni, Sara, Rademakers, Rosa, Redaelli, Veronica, Rossi, Giacomina , Thonberg, Håkan, Tiraboschi, Pietro , Verdelho, Ana, Warren, Jason D. , Binetti, Giuliano, Fallström, Marie, Fumagalli, Giorgio, Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Pievani, Michela, Premi, Enrico, Prioni, Sara, Redaelli, Veronica, Verdelho, Ana, Binetti, Giuliano , Redaelli, Veronica , Prioni, Sara , Fumagalli, Giorgio , Frisoni, Giovanni B. , Finger, Elizabeth C. , Rowe, James B , Rohrer, Jonathan D , Padovani, Alessandro , Tartaglia, Maria Carmela , Cash, David M , Vita, Enrico De , Black, Sandra E. , Rogaeva, Ekaterina A. , Swieten, John C. van , Masellis, Mario , (GENFI), GENetic Frontotemporal dementia Initiative, Binetti, Giuliano, Fallström, Marie, Ferreira, Carlos , Fox, Nick C. , Fumagalli, Giorgio, Jelic, Vesna, Jiskoot, Lize C. , Lombardi, Gemma, Maruta, Carolina, Nacmias, Benedetta , Pievani, Michela, Premi, Enrico, Prioni, Sara, Rademakers, Rosa , Redaelli, Veronica, Rossor, Martin N. , Scarpini, Elio , Verdelho, Ana, Binetti, Giuliano, Fallström, Marie, Fumagalli, Giorgio, Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Pievani, Michela, Premi, Enrico, Prioni, Sara, Redaelli, Veronica, Verdelho, Ana, Galimberti, Daniela , de Mendonça, Alexandre , Bocchetta, Martina , Tiraboschi, Pietro , Laforce, Robert , Graff, Caroline , Borroni, Barbara

Mayo Clinic

Brain | February 2, 2019 | Volume: 142 | Issue: 4 | Pages: 1108-1120

10.1093/brain/awz039 | PMID 30847466 Get It

Abstract Genetic forms of frontotemporal dementia are most commonly due to mutations in three genes, C9orf72, GRN or MAPT, with presymptomatic carriers from families representing those at risk. While cerebral blood flow shows differences between frontotemporal dementia and other forms of dementia, there is limited evidence of its utility in presymptomatic stages of frontotemporal dementia. This study aimed to delineate the cerebral blood flow signature of presymptomatic, genetic frontotemporal dementia using a voxel-based approach. In the multicentre GENetic Frontotemporal dementia Initiative (GENFI) study, we investigated cross-sectional differences in arterial spin labelling MRI-based cerebral blood flow between presymptomatic C9orf72, GRN or MAPT mutation carriers (n = 107) and non-carriers (n = 113), using general linear mixed-effects models and voxel-based analyses. Cerebral blood flow within regions of interest derived from this model was then explored to identify differences between individual gene carrier groups and to estimate a timeframe for the expression of these differences. The voxel-based analysis revealed a significant inverse association between cerebral blood flow and the expected age of symptom onset in carriers, but not non-carriers. Regions included the bilateral insulae/orbitofrontal cortices, anterior cingulate/paracingulate gyri, and inferior parietal cortices, as well as the left middle temporal gyrus. For all bilateral regions, associations were greater on the right side. After correction for partial volume effects in a region of interest analysis, the results were found to be largely driven by the C9orf72 genetic subgroup. These cerebral blood flow differences first appeared approximately 12.5 years before the expected symptom onset determined on an individual basis. Cerebral blood flow was lower in presymptomatic mutation carriers closer to and beyond their expected age of symptom onset in key frontotemporal dementia signature regions. These results suggest that arterial spin labelling MRI may be a promising non-invasive imaging biomarker for the presymptomatic stages of genetic frontotemporal dementia.
Identifying patient‐important outcomes in polycystic kidney disease: An international nominal group technique study
Cho, Yeoungjee , Sautenet, Bénédicte , Gutman, Talia , Rangan, Gopala K. , Craig, Jonathan C. , Ong, Albert , Chapman, Arlene B., Coolican, Helen, Kao, Juliana T‐W, Gansevoort, Ron T. , Harris, Tess , Torres, Vicente E. , Pei, York , Ryan, Jessica , Johnson, David W. , Viecelli, Andrea K. , Geneste, Claire, Oh, Yun Kyu , Teixeira‐Pinto, Armando , Logeman, Charlotte , Howell, Martin , Ju, Angela, Manera, Karine , Tong, Allison , Torres, Vicente E , Johnson, David W , Howell, Martin , Ong, Albert C M , Ahn, Curie , Kao, Juliana Tze‐Wah , Perrone, Ronald D. , Kerr, Peter G. , Kim, Hyunsuk , Kim, Yaerim , Cho, Yeoungjee

Mayo Clinic

Nephrology | January 21, 2019 | Volume: 24 | Issue: 12 | Pages: 1214-1224

10.1111/nep.13566 | PMID 30663163 Get It

ABSTRACTAimPatients with autosomal dominant polycystic kidney disease (ADPKD) are at increased risk of premature mortality, morbidities and complications, which severely impair quality of life. However, patient‐centered outcomes are not consistently reported in trials in ADPKD, which can limit shared decision‐making. We aimed to identify outcomes important to patients and caregivers and the reasons for their priorities.MethodsNominal group technique was adopted involving patients with ADPKD and caregivers who were purposively selected from eight centres across Australia, France and the Republic of Korea. Participants identified, ranked and discussed outcomes for trials in ADPKD. We calculated an importance score (0–1) for each outcome and conducted thematic analyses.ResultsAcross 17 groups, 154 participants (121 patients, 33 caregivers) aged 19 to 78 (mean 54.5 years) identified 55 outcomes. The 10 highest ranked outcomes were: kidney function (importance score 0.36), end‐stage kidney disease (0.32), survival (0.21), cyst size/growth (0.20), cyst pain/bleeding (0.18), blood pressure (0.17), ability to work (0.16), cerebral aneurysm/stroke (0.14), mobility/physical function (0.12), and fatigue (0.12). Three themes were identified: threatening semblance of normality, inability to control and making sense of diverse risks.ConclusionFor patients with ADPKD and their caregivers, kidney function, delayed progression to end‐stage kidney disease and survival were the highest priorities, and were focused on achieving normality, and maintaining control over health and lifestyle. Implementing these patient‐important outcomes may improve the meaning and relevance of trials to inform clinical care in ADPKD.
A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation.
Hendifar, Andrew , Shroff, Rachna T. , Leichman, Lawrence P., Epelbaum, Ron, Geva, Ravit , Kim, George P., Wolff, Robert A. , Allen, Andrew R., Giordano, Heidi, Raponi, Mitch , Isaacson, Jeffrey D., Rolfe, Lindsey, Vonderheide, Robert H. , Domchek, Susan M. , McWilliams, Robert R. , Alberts, Steven R. , Biankin, Andrew V.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS4161-TPS4161

10.1200/jco.2014.32.15_suppl.tps4161 Get It

Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.
Epelbaum, Ron, Semenisty, Valeriya, Geva, Ravit, Golan, Talia , Borazanci, Erkut , Wolpin, Brian M. , Ramirez, Robert A. , Becerra, Carlos, Shaw, Stephen M., Oberkovitz, Galia, Sorani, Ella, Lustig, Tzipora M, Haras, Abi Vainstein, Peled, Amnon , Hoff, Daniel D. Von , Borazanci, Erkut , Hidalgo, Manuel , Stemmer, Salomon M. , Borad, Mitesh J. , Park, Joon Oh , Pedersen, Katrina S. , Ramirez, Robert A

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 276-276

10.1200/jco.2018.36.4_suppl.276 Get It

276 Background: BL-8040 is a novel CXCR4 antagonist being developed for multiple oncology indications. Preclinical studies demonstrated that BL-8040 increases the number of immune cells in peripheral blood and promotes CD8+ T cell infiltration into orthotropic pancreatic mouse tumors, reducing tumor load. BL-8040 is being evaluated in a Phase 2a, multicenter, open label trial in patients with metastatic pancreatic cancer (the COMBAT study). Patients are undergoing a 5-day period of monotherapy in which they receive daily doses of BL-8040, followed by 21-day cycles in which patients receive one dose of pembrolizumab and 3 doses/week of BL-8040 until disease progression or discontinuation. To date, 32 patients have been enrolled. Methods: On Day 1 and Day 5, blood samples were taken at pre- and post-dosing, to evaluate peripheral immune cell subset frequency by flow cytometry. In addition, core biopsies were taken from liver metastases, where possible, to assess immune cell infiltration into tumors and the tumor microenvironment (TME). Results: Here we present interim PD biomarker data from the BL-8040 monotherapy portion of the trial. Flow cytometry shows that BL-8040 monotherapy caused an approximately two-fold reduction in frequency of peripheral T regulatory cells, but had no effect on the frequency of T cells, NKT cells or cell populations that contain B cells (CD3- CD56-). Additionally, BL-8040 remained bound to CXCR4 on peripheral immune cells throughout the period of monotherapy. Analysis of available biopsies (N = 7) shows an up to 15-fold increase in the CD3+ population, and up to two-fold increase of CD8+ cells, in the tumor periphery and TME of 43% (3/7) of the patients after five days of BL-8040 monotherapy compared to baseline. Conclusions: In summary, the PD biomarker results in humans support the proposed mechanism of action for BL-8040 that was based on preclinical mouse models. Analysis of tumor biopsies is ongoing, with an emphasis on investigating the effects of BL-8040 on tumor-resident immune cells and the TME. Clinical trial information: NCT02826486.
Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).
Cynthia, X. , Bose, Ron , Pegram, Mark D. , Blackwell, Kimberly , Bédard, Philippe L. , Hayes, Daniel F. , Russell, Christy , Forero, Andres , Bumb, Caroline, Al‐Kateb, Hussam , Gao, Feng , Freedman, Rachel A. , Goetz, Matthew P. , Niravath, Polly Ann , Tripathy, Debu , Cobleigh, Melody , Pluard, Timothy , Anders, Carey K. , Naughton, Michael J. , Ellis, Matthew J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 516-516

10.1200/jco.2016.34.15_suppl.516 Get It

RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.
Hendifar, Andrew , Geva, Ravit , Epelbaum, Ron, Vonderheide, Robert H. , Wolff, Robert A. , Giordano, Heidi, Goble, Sandra, Shroff, Rachna T. , Domchek, Susan M. , McWilliams, Robert R. , Biankin, Andrew V. , Alberts, Steven R. , Lin, Kevin

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4110-4110

10.1200/jco.2016.34.15_suppl.4110 Get It

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy
Chu, Edward , Allegra, Carmen J. , Tanigawara, Yusuke , Milano, G. , Diasio, Robert B. , Kim, Tae Won , Mathijssen, Ron H.J. , Muneoka, Katsuki, Diasio, Robert, Beumer, Jan Hendrik , Zhang, Li , Arnold, Dirk , Boku, Narikazu , Joerger, Markus

Mayo Clinic

Clinical Pharmacology & Therapeutics | June 20, 2018 | Volume: 105 | Issue: 3 | Pages: 598-613

10.1002/cpt.1124 | PMID 29923599 Get It

5‐Fluorouracil (5‐FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5‐FU therapy in patients with colorectal or head‐and‐neck cancer receiving common 5‐FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.
FP047POTENTIAL IMPACT OF TOLVAPTAN ON BLOOD PRESSURE IN THE TEMPO 3:4 PATIENT POPULATION
Chapman, Arlene B., Devusyt, Oliveir, Gansevoort, Ron T. , Perrone, R. D., Czerwiec, Frank S., Pao, Christina , Torres, Vicente E.

Mayo Clinic

Nephrology Dialysis Transplantation | May 18, 2018 | Volume: 33 | Issue: suppl_1 | Pages: i63-i63

10.1093/ndt/gfy104.fp047 Get It

Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Shroff, Rachna T. , Hendifar, Andrew , Geva, Ravit , Epelbaum, Ron, Rolfe, Lindsey, Goble, Sandra, Giordano, Heidi, Vonderheide, Robert H. , Lin, Kevin K. , McWilliams, Robert R. , Lin, Kevin , Biankin, Andrew V. , Domchek, Susan M.

Mayo Clinic

JCO Precision Oncology | May 16, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-15

10.1200/po.17.00316 | PMID 30051098 Get It

Purpose Pancreatic cancer has a poor prognosis and limited treatment options. Approximately 9% of pancreatic cancers harbor a germline or somatic BRCA1 or BRCA2 ( BRCA1/2) mutation. Because poly (ADP-ribose) polymerase inhibitors have significant activity in BRCA1/2-mutant ovarian and breast cancers, RUCAPANC investigated the efficacy and safety of rucaparib in BRCA1/2-mutant pancreatic cancer. Patients and Methods RUCAPANC enrolled patients with measurable locally advanced/metastatic pancreatic cancer who had received one to two prior chemotherapy regimens. Patients received oral rucaparib (600 mg twice daily) until disease progression. The primary end point was objective response rate. Results Nineteen patients were enrolled. Sixteen of 19 BRCA1/2 mutations were germline; three were somatic. Patients had received a median of two prior chemotherapy regimens. Four patients achieved a response; two partial responses and one complete response (CR) were confirmed (objective response rate, 15.8%; 3 of 19), with an additional CR unconfirmed. The disease control rate (CR, partial response, or stable disease for ≥ 12 weeks) was 31.6% (6 of 19) in all patients and 44.4% (4 of 9) in those who had received one prior chemotherapy regimen. As prespecified in the protocol, enrollment was stopped because of an insufficient response rate among the first 15 patients. Treatment-emergent adverse events included nausea (63.2%) and anemia (47.4%). Grade ≥ 3 adverse events included anemia (31.6%), fatigue (15.8%), and ascites (15.8%). Secondary resistance mutations were detected in circulating free tumor DNA in two patients with a germline BRCA2 mutation. These mutations are predicted to lead to the reversion of a somatic—not germline—mutation. Conclusion Rucaparib provided clinical benefit to patients with advanced pancreatic cancer and a BRCA1/2 mutation, and demonstrated an acceptable safety profile. Additional trials of rucaparib in this population are warranted.